Embattled J&J plant cited again by FDA

FDA inspectors aren't convinced that Johnson & Johnson ($JNJ) is doing enough to fix problems at its troubled Fort Washington, PA, plant. That's the facility that produced the children's drugs caught up in the massive recall earlier this year. Since then, it's been a major focus in J&J's efforts to fix its manufacturing slip-ups, which prompted more than a dozen recent recalls.

But in a recent visit to the McNeil Consumer Healthcare plant, which has been closed for an overhaul since April, FDA inspectors identified a number of quality control problems. The plant's staff didn't handle customer complaints properly, didn't fully review discrepancies in product batches and didn't keep proper records, the inspectors said.

The company says it's toiling to bring its processes up to snuff. In a statement, McNeil said it has been "working diligently to ensure that our manufacturing operations meet the level of quality that consumers and the FDA expect of us. While the company has made progress...this is an ongoing commitment."

Indeed. J&J has been reviewing its manufacturing and quality control companywide, a process that has resulted in a couple of new recalls in the last two months. A plant in Puerto Rico has been another focus of concern, as products made there turned up with a musty, moldy odor and had to be recalled. FDA inspectors have cited that plant for shortfalls as well.

- read the Reuters news

On-Demand Webinar

Leveraging A Medical Record-Enriched Patient Dataset for COVID-19 Research

You are invited to join a webinar that will explore the ways researchers can leverage this enriched dataset for important COVID-19 research. Sign up today for this informative webinar to learn how you can leverage one of the only medical record reviews solely using real-world data from hospitalized COVID-19 patients.

Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

New York's Covaxx has signed on with three South American nations to provide 140 million doses of its early-stage COVID-19 vaccine.

To get the COVID-19 vaccine out quickly, Pfizer has been running rehearsals at distribution sites, creating "growing confidence," U.S. officials said.